BIO-TECHNE (NASDAQ: TECH) and Sunesis Pharmaceuticals (NASDAQ:SNSS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.
This table compares BIO-TECHNE and Sunesis Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares BIO-TECHNE and Sunesis Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BIO-TECHNE||$563.00 million||9.74||$76.08 million||$3.05||47.99|
|Sunesis Pharmaceuticals||$2.54 million||57.17||-$38.02 million||($1.75)||-2.42|
BIO-TECHNE has higher revenue and earnings than Sunesis Pharmaceuticals. Sunesis Pharmaceuticals is trading at a lower price-to-earnings ratio than BIO-TECHNE, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
95.8% of BIO-TECHNE shares are held by institutional investors. Comparatively, 53.2% of Sunesis Pharmaceuticals shares are held by institutional investors. 3.4% of BIO-TECHNE shares are held by insiders. Comparatively, 10.2% of Sunesis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
BIO-TECHNE pays an annual dividend of $1.28 per share and has a dividend yield of 0.9%. Sunesis Pharmaceuticals does not pay a dividend. BIO-TECHNE pays out 42.0% of its earnings in the form of a dividend.
This is a breakdown of recent ratings and target prices for BIO-TECHNE and Sunesis Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BIO-TECHNE currently has a consensus price target of $148.75, suggesting a potential upside of 1.63%. Sunesis Pharmaceuticals has a consensus price target of $4.49, suggesting a potential upside of 5.97%. Given Sunesis Pharmaceuticals’ higher probable upside, analysts plainly believe Sunesis Pharmaceuticals is more favorable than BIO-TECHNE.
Volatility & Risk
BIO-TECHNE has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Comparatively, Sunesis Pharmaceuticals has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500.
BIO-TECHNE beats Sunesis Pharmaceuticals on 11 of the 16 factors compared between the two stocks.
BIO-TECHNE Company Profile
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world. The Clinical Controls segment develops and manufactures controls, calibrators, immunoassays and other reagents for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. It markets immunoassays on different testing platforms, including microtiter-plate based kits sold under the trade name Quantikine, and immunoassays based on planar spotted surfaces and microfluidic-based multiplex immunoassays on automated testing platform.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company’s other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton’s tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.
Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.